Intracavitary slow release paclitaxel polymer in a rodent model of mammary carcinoma

In this study, a pharmacokinetic analysis of the paclitaxel polymer formulation was performed. The formulation was injected subcutaneously in the lower left inguinal area in C3H-HeJ mice. The mice were observed daily for signs of toxicity and local tumor regrowth. Humane sacrifice was performed at d...

Full description

Saved in:
Bibliographic Details
Published in:Journal of bioactive and compatible polymers 2000, Vol.15 (1), p.85-88
Main Authors: BREGAZZI, V. S, DERNELL, W. S, HUBER, D. J, SCHOCHET, R, LAFFERTY, M, OGILVIE, G. K, WITHROW, S. J, POWERS, B. E, MANNING, M
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Blood
Cells
Chemotherapy
Controlled drug delivery
High performance liquid chromatography
Mathematical models
Medical sciences
Oncology
Pharmacokinetics
Pharmacology. Drug treatments
Statistical methods
Toxicity
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, a pharmacokinetic analysis of the paclitaxel polymer formulation was performed. The formulation was injected subcutaneously in the lower left inguinal area in C3H-HeJ mice. The mice were observed daily for signs of toxicity and local tumor regrowth. Humane sacrifice was performed at day 15 or sooner if tumor burden or systematic illness indicated the need for earlier sacrifice. Complete necropsies were performed and the local tumor site, lymph nodes, bone marrow, brain, liver, kidneys, spleen, heart, lungs, stomach and intestines removed and placed in formalin for histological assessment of toxicity, metastasis and/or tumor regrowth. Based on the results, it appears that the paclitaxel polymer delivery system decreased local tumor regrowth.
ISSN:0883-9115
1530-8030
DOI:10.1106/BLCC-E8VH-EKAN-GWGK